Results 131 to 140 of about 28,422 (269)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

, 2019
Objetivo: Mepolizumab está indicado como tratamiento adicional del asma eosinofílica refractaria grave. Las diferencias observadas en subgrupos poblacionales según recuento eosinofílico plasmático, existencia de pacientes con altos niveles de ...
Alarcón de la Lastra Romero, Catalina, Alegre del Rey, Emilio Jesús, García Mochón, Leticia, Gil Sierra, Manuel David, Sánchez Hidalgo, Marina   +4 more
core   +3 more sources

Differential Effects of Benralizumab and Mepolizumab on Pro‐Resolving Mediators

Allergy, EarlyView.
Jaime Bernaola, José Antonio Cañas, Álvaro Arranz‐Fragua, José Manuel Rodrigo‐Muñoz, Daniel Rodríguez‐González, Antonio Serrano‐Santiago, Gema Guillén‐Sánchez, Alma Martínez Fernández, Marcela Valverde‐Monge, Diana Betancor, Erwin Javier Pinillos‐Robles, Claudia Rodríguez‐Busto, María Jesús Rodríguez‐Nieto, Joaquín Sastre, Victoria del Pozo   +14 more
wiley   +1 more source

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla, Roberta Fachini Jardim Criado, Kanokvalai Kulthanan, Emek Kocatürk, Ivan Cherrez‐Ojeda, Ana Maria Giménez‐Arnau, Marcus Maurer, Luis Felipe Ensina, Jonathan A. Bernstein, Michihiro Hide, Sergio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Gabriela Dias, Paraskevi Xepapadak, Priyanshi Dangi, Indrashis Podder, Vesna Trajkova, Natasa Teovska Mitrevska, Iman Hamed Nasr, Bushra Al Hinai, Joanna Bartosińska, Dorota Krasowska, Paulina Szczepanik‐Kułak, Hilal Gungor, Deniz Ozceker, Kübra Çiçek, Esen Özkaya, Yasemin Erdem, Mücahit Ergün, Mustafa Tosun, Rabia Oztas Kara, Jie Li, Anastasia Allenova, Paulo Ricardo Criado   +33 more
wiley   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data

Педиатрическая фармакология, 2016
Background: Omalizumab is the first and yet the only biopreparation for asthma which combines high efficiency and high cost. The clinical-economic expediency of using omalizumab in asthmatic children has not been previously studied in Russia.Objective ...
A. S. Kolbin, L. S. Namazova-Baranova, E. A. Vishneva, M. Y. Frolov, T. L. Galankin, A. A. Alekseeva, E. A. Dobrynina   +6 more
doaj   +1 more source

Algorithms of Patient Selection for Allergen Immunotherapy

Allergy, EarlyView.
U. Petra Zieglmayer, Stefania Arasi, Thomas Eiwegger, Thilo Jakob, Ludger Klimek, Markus Ollert   +5 more
wiley   +1 more source

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger, Kaitlyn Chan, Alphonsus Yip, Xingyue Maria Wang, Conor Broderick, Bernd Arents, Karin van Bart, Kilian Eyerich, Joseph Rastrick, Stephan Weidinger, Carsten Flohr, on behalf of the BIOMAP Consortium   +11 more
wiley   +1 more source

Omalizumab is Effective and Safe in the Treatment of Japanese Cedar Pollen-induced Seasonal Allergic Rhinitis

Allergology International, 2006
Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Omalizumab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been proven to reduce symptoms associated with SAR.
Kimihiro Okubo, Satoshi Ogino, Toshikazu Nagakura, Takeru Ishikawa   +3 more
doaj   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

Case Reports in Medicine, 2015
Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria.
Misbah Nasheela Ghazanfar, Simon Francis Thomsen   +1 more
doaj   +1 more source